P&U Will Continue To Pursue Ellence Metastatic Breast Cancer Indication
Executive Summary
Pharmacia & Upjohn will continue to pursue a first-line metastatic breast cancer indication for its anthracycline antibiotic Ellence following FDA's Oncologic Drugs Advisory Committee's rejection of the indication June 7.